Recon: GSK to purchase RAPT Therapeutics, food allergy drugmaker, for $2.2 billion; Corvus’ therapy demonstrates positive results in early-stage eczema study
ReconJason Scott
Biologics/ biosimilars/ vaccinesGlobalMedical DevicesPharmaceuticalsReconJason ScottBiologics/ biosimilars/ vaccinesGlobalMedical DevicesPharmaceuticals